Association of immune-related adverse events with COVID-19 pneumonia in lung cancer patients receiving immune checkpoint inhibitors: a cross-sectional study in China

BACKGROUND: Immune checkpoint inhibitors (ICIs) are commonly used to treat lung cancer patients, but their use can lead to immune-related adverse events (irAEs), which pose a challenge for treatment strategies. The impact of irAEs on the incidence of COVID-19 pneumonia in lung cancer patients during...

Descripción completa

Detalles Bibliográficos
Autores principales: Che, Kaijun, Hong, Chen, He, Yanqing, Peng, Duanyang, Zeng, Zhimin, Liu, Anwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629076/
https://www.ncbi.nlm.nih.gov/pubmed/37932685
http://dx.doi.org/10.1186/s12885-023-11584-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629076/
https://www.ncbi.nlm.nih.gov/pubmed/37932685
http://dx.doi.org/10.1186/s12885-023-11584-w

Ejemplares similares